Successful Treatment with Alectinib for Choroidal Metastasis in Anaplastic Lymphoma Kinase Rearranged Non-small Cell Lung Cancer

Tomoko Funazo; Kyohei Morita; Naoya Ikegami; Chisato Konishi; Satoshi Nakao; Ryo Ariyasu; Masato Taki; Kazuhiko Nakagawa; Moon Hee Hwang; Chie Yoshimura; Toshiaki Wakayama; Yasuo Nishizaka

doi:10.2169/internalmedicine.8488-16

This article has now been updated. Please use the final version.

Successful Treatment with Alectinib for Choroidal Metastasis in Anaplastic Lymphoma Kinase Rearranged Non-small Cell Lung Cancer

Tomoko Funazo, Kyohei Morita, Naoya Ikegami, Chisato Konishi, Satoshi Nakao, Ryo Ariyasu, Masato Taki, Kazuhiko Nakagawa, Moon Hee Hwang, Chie Yoshimura, Toshiaki Wakayama, Yasuo Nishizaka

Author information

Tomoko Funazo
Department of Respiratory Medicine, Kyoto University, Japan
Kyohei Morita
Department of Respiratory Medicine, Osaka Red Cross Hospital, Japan
Naoya Ikegami
Department of Respiratory Medicine, Osaka Red Cross Hospital, Japan
Chisato Konishi
Department of Respiratory Medicine, Osaka Red Cross Hospital, Japan
Satoshi Nakao
Department of Respiratory Medicine, Osaka Red Cross Hospital, Japan
Ryo Ariyasu
Department of Respiratory Medicine, Osaka Red Cross Hospital, Japan
Masato Taki
Department of Respiratory Medicine, Osaka Red Cross Hospital, Japan
Kazuhiko Nakagawa
Department of Respiratory Medicine, Osaka Red Cross Hospital, Japan
Moon Hee Hwang
Department of Respiratory Medicine, Osaka Red Cross Hospital, Japan
Chie Yoshimura
Department of Respiratory Medicine, Osaka Red Cross Hospital, Japan
Toshiaki Wakayama
Department of Respiratory Medicine, Osaka Red Cross Hospital, Japan
Yasuo Nishizaka
Department of Respiratory Medicine, Osaka Red Cross Hospital, Japan

Keywords: choroidal metastasis, anaplastic lymphoma kinase (ALK), alectinib, non-small cell lung cancer (NSCLC)

JOURNAL OPEN ACCESS Advance online publication

Article ID: 8488-16

DOI https://doi.org/10.2169/internalmedicine.8488-16

The final version of this article is now available: Vol. 56 (2017), No. 17 pp. 2317-2320

Details

Abstract

Choroidal metastasis is rare in cancer patients and it may cause visual disturbances that reduce their quality of life. In non-small cell lung cancer (NSCLC), targeted therapy against actionable driver mutations has gradually replaced radiotherapy as the treatment of choice for choroidal metastasis. Recently, there have been several case reports of choroidal metastasis in patients with anaplastic lymphoma kinase (ALK)-rearranged NSCLC. We herein report the case of a 40-year-old Japanese woman diagnosed with choroidal metastasis of an ALK-rearranged NSCLC who received alectinib as the first-line chemotherapy. Alectinib may be the best treatment for choroidal metastasis in patients harboring an ALK translocation because of its favorable side effect profile involving visual disturbances.

Corresponding author

Register with J-STAGE for free!